The soy-derived peptide lunasin inhibited histone acetylation (an epigenetic change linked to cancer) in a dose-dependent manner and remained intact and active after oral consumption in rats.
Intact & active after oral feedingLunasin was found intact in rat blood and liver after oral consumption and still inhibited histone acetylation — rare for a dietary peptide
What the researchers found
Lunasin from various Korean soybean varieties inhibited core histone H3 and H4 acetylation in a dose-dependent manner, with the degree of inhibition correlating to the amount of lunasin present. Both natural soy-derived lunasin and synthetic lunasin showed the same activity.
Critically for practical relevance, lunasin in enriched soy survived in vitro pepsin digestion and was found intact in blood and liver tissue of rats fed lunasin-enriched soy (LES). The extracted lunasin retained its histone acetylation inhibitory activity, demonstrating oral bioavailability — a rare achievement for a dietary peptide of this size.
Why it matters
Most dietary peptides are destroyed during digestion, making them unlikely to have systemic effects. Lunasin is exceptional because it survives stomach acid and reaches the bloodstream intact. Its proposed mechanism — blocking histone acetylation to prevent cancer cell transformation — represents an epigenetic approach to cancer prevention that is fundamentally different from conventional antioxidant-based dietary cancer prevention theories.
How the study worked
Researchers extracted lunasin from multiple Korean soybean varieties and measured its presence by immunostaining. Histone acetylation inhibition was quantified using a non-radioactive histone acetyltransferase assay. Stability was tested through in vitro pepsin digestion. Bioavailability was assessed in rats fed lunasin-enriched soy, with lunasin extracted from blood and liver tissue and tested for intact structure and biological activity.
What this study cannot tell us
This is a preclinical study with in vitro and rat data only — no human evidence exists for lunasin's cancer-preventive effects. The correlation between lunasin content and histone acetylation inhibition doesn't establish that eating soy prevents cancer. The rat bioavailability data doesn't specify what percentage of ingested lunasin reaches the bloodstream intact. The mechanistic model linking histone acetylation inhibition to cancer prevention, while plausible, has not been validated in long-term cancer outcome studies.
How to read the evidence
This is a preclinical study combining in vitro histone assays with animal bioavailability data. While it provides strong mechanistic evidence, no human clinical data supports lunasin's cancer-preventive effects. The evidence is promising but early-stage.
When this study was published
Published in 2007, this was an early characterization of lunasin's bioavailability and mechanism. Subsequent research has expanded on these findings, though lunasin has not yet progressed to clinical cancer prevention trials.
The bigger picture
Lunasin occupies a unique position in the bioactive peptide field — it's one of the few food-derived peptides with a well-characterized epigenetic mechanism of action. While most food peptides work through enzyme inhibition (like ACE inhibitors from milk), lunasin targets the fundamental machinery of gene expression. This research contributed to the broader understanding that dietary peptides can influence epigenetic processes, and lunasin has since been studied for anti-inflammatory, cholesterol-lowering, and immunomodulatory effects.
Questions still open
- Is lunasin bioavailable in humans at concentrations sufficient to inhibit histone acetylation in target tissues?
- Does regular soy consumption provide enough lunasin for meaningful cancer-preventive effects, or would concentrated supplementation be needed?
Common questions
What is histone acetylation and why does blocking it prevent cancer?
Can eating soy give you cancer-preventive amounts of lunasin?
Read the original research
Inhibition of core histone acetylation by the cancer preventive peptide lunasin.
Journal of agricultural and food chemistry, 55(3), 632-7
Citation
Jeong, Hyung Jin; Jeong, Jin Boo; Kim, Dae Seop; de Lumen, Ben O. (2007). Inhibition of core histone acetylation by the cancer preventive peptide lunasin.. Journal of agricultural and food chemistry, 55(3), 632-7.